Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and efficacy of K-604 for the treatment of atherosclerosis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| low dose K-604 | Experimental |
| |
| high dose K-604 | Experimental |
| |
| placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| K-604 | Drug | K-604 is given for 26 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in plaque composition over 6 months | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in plaque size over 6 months. | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chandler | Arizona | United States | ||||
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Other |
placebo tablets are given for 26 weeks |
|
| Litchfield Park |
| Arizona |
| United States |
| Phoenix | Arizona | United States |
| Los Angeles | California | United States |
| San Diego | California | United States |
| Clearwater | Florida | United States |
| Jacksonville | Florida | United States |
| St Louis | Missouri | United States |
| Buffalo | New York | United States |
| Oklahoma City | Oklahoma | United States |
| Carrollton | Texas | United States |
| Dallas | Texas | United States |
| Houston | Texas | United States |
| Plano | Texas | United States |
| Norfolk | Virginia | United States |
| Virginia Beach | Virginia | United States |
| Olympia | Washington | United States |
| Renton | Washington | United States |
| Seattle | Washington | United States |
| ID | Term |
|---|---|
| D050197 | Atherosclerosis |
| D002340 | Carotid Artery Diseases |
| ID | Term |
|---|---|
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C520671 | (2-(4-(2-benzimidazol-2ylthio)ethyl)piperazin-1yl)-N-(2,4-bis(methylthio)-6-methyl-3-pyridyl)acetamide |
Not provided
Not provided
Not provided